<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5840979 - Useful in the treatment and prevention of diseases in which cell death ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Useful in the treatment and prevention of diseases in which cell death occurs by apoptosis"><meta name="DC.contributor" content="David Durden" scheme="inventor"><meta name="DC.contributor" content="Alick Paterson" scheme="inventor"><meta name="DC.contributor" content="Bruce Davis" scheme="inventor"><meta name="DC.contributor" content="Lillian Dyck" scheme="inventor"><meta name="DC.contributor" content="Peter Yu" scheme="inventor"><meta name="DC.contributor" content="Xinmin Li" scheme="inventor"><meta name="DC.contributor" content="Alan Boulton" scheme="inventor"><meta name="DC.contributor" content="University Of Saskatchewan" scheme="assignee"><meta name="DC.date" content="1997-7-14" scheme="dateSubmitted"><meta name="DC.description" content="The present invention relates to the use of a group of propargylamines of the general formula (I) ##STR1## wherein R1 is hydrogen or CH3 and R2 is (CH2)n CH3 and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula I are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds."><meta name="DC.date" content="1998-11-24" scheme="issued"><meta name="DC.relation" content="US:5169868" scheme="references"><meta name="citation_reference" content="Ansari et al., J. Neuroscience, 13(9), 4042 4053 (1993)."><meta name="citation_reference" content="Ansari et al., J. Neuroscience, 13(9), 4042-4053 (1993)."><meta name="citation_reference" content="Berry et al., Progress in Neurobiology, 44, 141 161 (1994)."><meta name="citation_reference" content="Berry et al., Progress in Neurobiology, 44, 141-161 (1994)."><meta name="citation_reference" content="Boissier et al., Therapie, XXII, 367 373 (1967) (See English Summary on p. 373)."><meta name="citation_reference" content="Boissier et al., Therapie, XXII, 367-373 (1967) (See English Summary on p. 373)."><meta name="citation_reference" content="Davis et al., American Society for Neurochemistry (Mar. 1995) (Abstract)."><meta name="citation_reference" content="Finberg et al., J. Neural Transm., 48, 95 101 (1996)."><meta name="citation_reference" content="Finberg et al., J. Neural Transm., 48, 95-101 (1996)."><meta name="citation_reference" content="Grace et al., Chem. Res. Toxicol., 7, 286 290 (1994)."><meta name="citation_reference" content="Grace et al., Chem. Res. Toxicol., 7, 286-290 (1994)."><meta name="citation_reference" content="Knollema et al., Stroke, 26(10), 1883 1887 (1995)."><meta name="citation_reference" content="Knollema et al., Stroke, 26(10), 1883-1887 (1995)."><meta name="citation_reference" content="Lai et al., Toxicology and Applied Pharmacology, 142, 186 191 (1997)."><meta name="citation_reference" content="Lai et al., Toxicology and Applied Pharmacology, 142, 186-191 (1997)."><meta name="citation_reference" content="Mytilineou et al., J. Neurochemistry, 68(1), 33 39 (1997)."><meta name="citation_reference" content="Mytilineou et al., J. Neurochemistry, 68(1), 33-39 (1997)."><meta name="citation_reference" content="Mytilineou et al., J. Neurochemistry, 68(1), 434 436 (1997)."><meta name="citation_reference" content="Mytilineou et al., J. Neurochemistry, 68(1), 434-436 (1997)."><meta name="citation_reference" content="Oh et al., J. Neuroscience Research, 38, 64 74 (1994)."><meta name="citation_reference" content="Oh et al., J. Neuroscience Research, 38, 64-74 (1994)."><meta name="citation_reference" content="Paterson et al., J. Neurochemistry, (in press) (1997)."><meta name="citation_reference" content="Paterson et al., Neuroscience and Biobehavioral Reviews, 20, 1 6 (1996)."><meta name="citation_reference" content="Paterson et al., Neuroscience and Biobehavioral Reviews, 20, 1-6 (1996)."><meta name="citation_reference" content="Paterson et al., Society for Neuroscience, 23, Abstract 880.6 (1997)."><meta name="citation_reference" content="Rideout et al., Society for Neuroscience, 23, Abstract 34.4 (1997)."><meta name="citation_reference" content="Salo et al., J. Neuroscience Research, 31, 394 400 (1992)."><meta name="citation_reference" content="Salo et al., J. Neuroscience Research, 31, 394-400 (1992)."><meta name="citation_reference" content="Tatton et al., J. Neurochemistry, 63(4), 1572 1575 (1994)."><meta name="citation_reference" content="Tatton et al., J. Neurochemistry, 63(4), 1572-1575 (1994)."><meta name="citation_reference" content="Tatton et al., J. Neuroscience Research, 30(4), 666 672 (1991)."><meta name="citation_reference" content="Tatton et al., J. Neuroscience Research, 30(4), 666-672 (1991)."><meta name="citation_reference" content="Tatton et al., Neurology, 47(3), S171 S183 (1996)."><meta name="citation_reference" content="Tatton et al., Neurology, 47(3), S171-S183 (1996)."><meta name="citation_reference" content="Wu et al., J. Neural Trasm., 100, 53 61 (1995)."><meta name="citation_reference" content="Wu et al., J. Neural Trasm., 100, 53-61 (1995)."><meta name="citation_reference" content="Yoles et al., Society for Neuroscience, 21, 562, Abstract 230.18 (1995)."><meta name="citation_reference" content="Yoshida et al., Xenobiotica, 16(2), 129 136 (1986)."><meta name="citation_reference" content="Yoshida et al., Xenobiotica, 16(2), 129-136 (1986)."><meta name="citation_reference" content="Yu et al., J. Medicinal Chemistry, 35(20), 3705 3713 (1992)."><meta name="citation_reference" content="Yu et al., J. Medicinal Chemistry, 35(20), 3705-3713 (1992)."><meta name="citation_reference" content="Yu et al., J. Neurochemistry, 63(5), 1820 1828 (1994)."><meta name="citation_reference" content="Yu et al., J. Neurochemistry, 63(5), 1820-1828 (1994)."><meta name="citation_reference" content="Yu et al., N. Neurochemistry, 62(2), 697 704 (1994)."><meta name="citation_reference" content="Yu et al., N. Neurochemistry, 62(2), 697-704 (1994)."><meta name="citation_patent_number" content="US:5840979"><meta name="citation_patent_application_number" content="US:08/891,904"><link rel="canonical" href="http://www.google.com/patents/US5840979"/><meta property="og:url" content="http://www.google.com/patents/US5840979"/><meta name="title" content="Patent US5840979 - Useful in the treatment and prevention of diseases in which cell death occurs by apoptosis"/><meta name="description" content="The present invention relates to the use of a group of propargylamines of the general formula (I) ##STR1## wherein R1 is hydrogen or CH3 and R2 is (CH2)n CH3 and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula I are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds."/><meta property="og:title" content="Patent US5840979 - Useful in the treatment and prevention of diseases in which cell death occurs by apoptosis"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("jy3uU4H6PKSlsQSy4YF4"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("DEU"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("jy3uU4H6PKSlsQSy4YF4"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("DEU"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5840979?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5840979"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=r-VIBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5840979&amp;usg=AFQjCNH8ca0IUp34XvP_WaiSg-M6PMrfbg" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5840979.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5840979.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5840979" style="display:none"><span itemprop="description">The present invention relates to the use of a group of propargylamines of the general formula (I) ##STR1## wherein R1 is hydrogen or CH3 and R2 is (CH2)n CH3 and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death...</span><span itemprop="url">http://www.google.com/patents/US5840979?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5840979 - Useful in the treatment and prevention of diseases in which cell death occurs by apoptosis</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5840979 - Useful in the treatment and prevention of diseases in which cell death occurs by apoptosis" title="Patent US5840979 - Useful in the treatment and prevention of diseases in which cell death occurs by apoptosis"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5840979 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/891,904</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Nov 24, 1998</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jul 14, 1997</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Jul 14, 1997</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Lapsed</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2295483A1">CA2295483A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2295483C">CA2295483C</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69813228D1">DE69813228D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0996612A2">EP0996612A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0996612B1">EP0996612B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6251950">US6251950</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1999003817A2">WO1999003817A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1999003817A3">WO1999003817A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1999003817B1">WO1999003817B1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08891904, </span><span class="patent-bibdata-value">891904, </span><span class="patent-bibdata-value">US 5840979 A, </span><span class="patent-bibdata-value">US 5840979A, </span><span class="patent-bibdata-value">US-A-5840979, </span><span class="patent-bibdata-value">US5840979 A, </span><span class="patent-bibdata-value">US5840979A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22David+Durden%22">David Durden</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Alick+Paterson%22">Alick Paterson</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Bruce+Davis%22">Bruce Davis</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Lillian+Dyck%22">Lillian Dyck</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Peter+Yu%22">Peter Yu</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Xinmin+Li%22">Xinmin Li</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Alan+Boulton%22">Alan Boulton</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22University+Of+Saskatchewan%22">University Of Saskatchewan</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5840979.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5840979.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5840979.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (1),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (45),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (9),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (12),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (8)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5840979&usg=AFQjCNHLg9PFu0o70S9yeYs0dCzocXIwdQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5840979&usg=AFQjCNGV9dnaw_Xj-XOc02Ct9spzeo229Q">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5840979A%26KC%3DA%26FT%3DD&usg=AFQjCNGV7tNGSq8b2JIJmOxPsY8eNzEMRQ">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129020201" lang="EN" load-source="ifi">Useful in the treatment and prevention of diseases in which cell death occurs by apoptosis</invention-title></span><br><span class="patent-number">US 5840979 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA131527303" lang="EN" load-source="patent-office"> <div class="abstract">The present invention relates to the use of a group of propargylamines of the general formula (I) ##STR1## wherein R<sup>1</sup> is hydrogen or CH<sub>3</sub> and R<sup>2</sup> is (CH<sub>2</sub>)<sub>n</sub> CH<sub>3</sub> and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula I are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(2)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5840979-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5840979-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5840979-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5840979-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(9)</span></span></div><div class="patent-text"><div mxw-id="PCLM59497233" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>We claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A compound having the formula I: ##STR14## wherein R<sup>1</sup> =H, CH<sub>3</sub> ;<div class="claim-text">R<sup>2</sup> =CH<sub>3</sub> (CH<sub>2</sub>)<sub>n</sub> ;<div class="claim-text">and n represents an integer in the range from 0 to 16, with the provisos that:</div> </div> <div class="claim-text">(i) if R<sup>1</sup> is H, then n is not 4 or less;</div> <div class="claim-text">(ii) if R<sup>1</sup> is CH<sub>3</sub>, then n is not 0; and</div> <div class="claim-text">(iii) if R<sup>1</sup> is CH<sub>3</sub> and n is 1 or 4, then the compound of formula (I) is in the form of a substantially pure enantiomer;<div class="claim-text">or a pharmaceutically acceptable salt thereof.</div> </div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. A compound according to claim 1 in which R<sup>1</sup> differs from R<sup>2</sup>, as a substantially pure enantiomer in the R-configuration.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. A compound according to claim 1 in which R<sup>1</sup> differs from R<sup>2</sup>, as a substantially pure enantiomer in the S-configuration.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. A compound according to claim 1, wherein said compound of formula (I) is selected from the group consisting of:<div class="claim-text">(R)-N-(2-butyl)propargylamine;</div> <div class="claim-text">(R)-N-(2-pentyl)propargylamine;</div> <div class="claim-text">(R)-N-(2-hexyl)propargylamine;</div> <div class="claim-text">(R)-N-(2-heptyl)propargylamine;</div> <div class="claim-text">(R)-N-(2-octyl)propargylamine;</div> <div class="claim-text">(R)-N-(2-nonyl)propargylamine;</div> <div class="claim-text">(R)-N-(2-decyl)propargylamine;</div> <div class="claim-text">(R)-N-(2-undecyl)propargylamine;</div> <div class="claim-text">(R)-N-(2-dodecyl)propargylamine;<div class="claim-text">or a pharmaceutically acceptable salt thereof.</div> </div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. A compound according to claim 1, wherein said compound of formula (I) is selected from the group consisting of:<div class="claim-text">(S)-N-(2-butyl)propargylamine;</div> <div class="claim-text">(S)-N-(2-pentyl)propargylamine;</div> <div class="claim-text">(S)-N-(2-hexyl)propargylamine;</div> <div class="claim-text">(S)-N-(2-heptyl)propargylamine;</div> <div class="claim-text">(S)-N-(2-octyl)propargylamine;</div> <div class="claim-text">(S)-N-(2-nonyl)propargylamine;</div> <div class="claim-text">(S)-N-(2-decyl)propargylamine;</div> <div class="claim-text">(S)-N-(2-undecyl)propargylamine;</div> <div class="claim-text">(S)-N-(2-dodecyl)propargylamine;<div class="claim-text">or a pharmaceutically acceptable salt thereof.</div> </div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. A compound according to claim 1, wherein said compound of formula (I) is selected from the group consisting of:<div class="claim-text">N-(1-heptyl)propargylamine;</div> <div class="claim-text">N-(1-octyl)propargylamine;</div> <div class="claim-text">N-(1-nonyl)propargylamine;</div> <div class="claim-text">N-(1-decyl)propargylamine;</div> <div class="claim-text">N-(1-undecyl)propargylamine;</div> <div class="claim-text">N-(1-dodecyl)propargylamine;<div class="claim-text">or a pharmaceutically acceptable salt thereof.</div> </div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. A compound according to claim 1 in the form of the hydrochloride salt.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. A compound according to claim 1 wherein n is an integer from 1 to 12.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. A compound according to claim 1 wherein n is an integer from 1 to 9.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67211098" lang="EN" load-source="patent-office" class="description">
    <heading>FIELD OF THE INVENTION</heading> <p>The invention relates to a class of propargylamines, their salts and to pharmaceutical compositions containing such compounds. The compounds have cellular rescue properties which make them useful in the treatment and prevention of diseases in which cell death occurs by apoptosis.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>Neurodegenerative disorders of both acute types (e.g. stroke, head trauma, Bell's palsy, spinal cord and other nerve crush injuries) and chronic types (e.g. Alzheimer's disease, Parkinson's disease, Picks's disease, amyotrophic lateral sclerosis, Huntington's disease, glaucoma, as well as idiopathic neuropathies) are responsible for enormous human suffering, are a burden on health care systems and result in significant economic loss. A drug or treatment which could prevent, delay or alleviate one or more of these conditions would be of immense value.</p>
    <p>R-Deprenyl hydrochloride (selegiline, L-deprenyl) has been demonstrated to be an effective adjuvant to L-dopa in the treatment of Parkinson's disease and, in early otherwise untreated cases, it has more recently been reported to delay onset of symptoms when administered alone. It has also been claimed that the use of deprenyl improved the clinical condition of some Alzheimer patients and the symptoms of attention deficit disorder in Tourette's syndrome patients. In addition, it has been observed to prolong life span and sexual activity in rodents and humans.</p>
    <p>Initially, the improvement in Parkinson's and other patients was ascribed to the protection of neurons by the MAO-B inhibitory properties of deprenyl. However, studies of the effect of deprenyl on neuronal survival in N-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-induced Parkinsonism, axotomized immature facial motoneurons in rats, and hippocampal neuron death following ischemia or excitotoxin insult have shown that survival is increased by a mechanism which is independent of monoamine oxidase type B (MAO-B) inhibition. Studies with PC12 cells have shown that deprenyl can prevent apoptosis by a mechanism which involves selective alterations in gene expression to block the loss of mitochondrial function which in turn would commit these cells to apoptosis. Deprenyl has also been shown to prevent N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)-induced degeneration of rat brain noradrenergic axons and terminals. The concentrations of deprenyl required to prevent apoptosis are at least an order of magnitude lower than the minimum necessary for MAO-B inhibition in some of these models. Furthermore, not all MAO-B inhibitors are effective in rescuing damaged neurons.</p>
    <p>Deprenyl is metabolized to amphetamine and methamphetamine which have been observed to be neurotoxic even at quite low concentrations, which creates a possible problem with deprenyl as a neuronal rescue drug. Similarly deprenyl has been shown to enhance the cytotoxicity of dopamine towards catecholaminergic neuroblastoma SH-SY5Y cells. Deprenyl has been demonstrated to be a substrate for cytochrome P450 enzymes, which mediate the dealkylation process leading to the observed metabolites, methamphetamine and desmethyldeprenyl. Desmethyldeprenyl is active as an anti-apoptotic drug and studies involving the inhibition of P450 enzymes have shown that desmethyldeprenyl is the active component when deprenyl is given since pretreatment with a P450 inhibitor such as proadifen eliminates the neurorescue properties of deprenyl. It has also been reported that the desmethyldeprenyl-like compound, N-propargyl-1-aminoindan, is effective in enhancing the in vitro neuronal survival after glutamate toxicity.</p>
    <p>Recently, some aliphatic analogues of deprenyl have proven to be as effective MAO-B inhibitors as deprenyl. As with deprenyl, it is the R-enantiomers which are active. They have also been shown to protect and rescue damaged neurons in the same models of neurodegeneration described above for deprenyl.</p>
    <p>The aliphatic propargylamines identified in this application are active as antiapoptotic compounds.</p>
    <heading>DESCRIPTION OF THE INVENTION</heading> <p>The present invention relates to a group of propargylamines of general formula (I) ##STR2## wherein R<sup>1</sup> is hydrogen or CH<sub>3</sub> and R<sup>2</sup> is (CH<sub>2</sub>)<sub>n</sub> CH<sub>3</sub> and n is 0 or an integer from 1 to 16, preferably 1 to 10, more preferably 1 to 5, and the salts thereof, particularly pharmaceutically acceptable salts.</p>
    <p>Compounds of the general formula (I) in which R<sup>1</sup> differs from R<sup>2</sup> are chiral. It has been found that the R-enantiomers are useful as cellular rescue agents for the treatment and prevention of diseases in which cell death occurs by apoptosis, such as those mentioned above. This effect is observed at doses much lower than those required for MAO-B inhibition. The S-enantiomers do not prevent apoptosis but can antagonise the anti-apoptotic actions of the R-enantiomers, and are useful as research tools. The achiral compounds display cellular rescue properties.</p>
    <p>The racemates are useful as intermediates in the preparation of R- and S-enantiomers. Methods of separating racemates are known. Suitable methods include fractional crystallization of a suitable salt, chromatography and preparation of for example N-acetyl derivatives, followed by deacetylation of one enantiomer with a stereospecific enzyme. It is preferred, however, to make chiral compounds of formula (I) from chiral reactants, using reactions that do not destroy the stereochemistry. When referring to enantiomers, it is preferred that an enantiomer shall not contain more than about 3% of the enantiomer of the opposite configuration. It is particularly preferred that an enantiomer contain less than about 1% of the enantiomer of the opposite configuration.</p>
    <p>The invention relates as well to the use of compounds of the general formula I, as defined above, and salts thereof, as cellular rescue agents for the treatment and prevention of diseases in which cell death occurs by apoptosis including stroke, head trauma, Bell's palsy, spinal cord and other nerve crush injuries, Alzheimer's disease, Parkinson's disease, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, cardiac myopathies, nephropathy, retinopathy, diabetic complications, glaucoma, as well as idiopathic neuropathies.</p>
    <heading>DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS</heading> <p>The present invention relates to a group of propargylamines of general formula (I), ##STR3## wherein R<sup>1</sup> is hydrogen or CH<sub>3</sub> and R<sup>2</sup> is (CH<sub>2</sub>)<sub>n</sub> CH<sub>3</sub> where n is an integer from 0 to 16, and salts thereof, and their use as cellular rescue agents for the treatment and prevention of diseases in which cell death occurs by apoptosis, as mentioned above.</p>
    <p>Preferred compounds of the invention include:</p>
    <p>N-(ethyl)propargylamine;</p>
    <p>N-(1-Propyl)propargylamine;</p>
    <p>N-(2-Propyl)propargylamine;</p>
    <p>N-(1-Butyl)propargylamine;</p>
    <p>N-(1-Pentyl)propargylamine;</p>
    <p>N-(1-Hexyl)propargylamine;</p>
    <p>N-(1-Heptyl)propargylamine;</p>
    <p>N-(1-Octyl)propargylamine;</p>
    <p>N-(1-Nonyl)propargylamine;</p>
    <p>N-(1-Decyl)propargylamine;</p>
    <p>N-(1-Undecyl)propargylamine;</p>
    <p>N-(1-Dodecyl)propargylamine;</p>
    <p>(R)-N-(2-Butyl)propargylamine;</p>
    <p>(R)-N-(2-Pentyl)propargylamine;</p>
    <p>(R)-N-(2-Hexyl)propargylamine;</p>
    <p>(R)-N-(2-Heptyl)propargylamine;</p>
    <p>(R)-N-(2-Octyl)propargylamine;</p>
    <p>(R)-N-(2-Nonyl)propargylamine;</p>
    <p>(R)-N-(2-Decyl)propargylamine;</p>
    <p>(R)-N-(2-Undecyl)propargylamine;</p>
    <p>(R)-N-(2-Dodecyl)propargylamine;</p>
    <p>The S-enantiomers antagonize the effect of the R-enantiomers, and are useful as research tools. Preferred compounds of the S-configuration are:</p>
    <p>(S)-N-(2-Butyl)propargylamine;</p>
    <p>(S)-N-(2-Pentyl)propargylamine;</p>
    <p>(S)-N-(2-Hexyl)propargylamine;</p>
    <p>(S)-N-(2-Heptyl)propargylamine;</p>
    <p>(S)-N-(2-Octyl)propargylamine;</p>
    <p>(S)-N- (2-Nonyl)propargylamine;</p>
    <p>(S)-N-(2-Decyl)propargylamine;</p>
    <p>(S)-N-(2-Undecyl)propargylamine;</p>
    <p>(S)-N-(2-Dodecyl)propargylamine;</p>
    <p>Compounds of formula (I) in which R<sup>1</sup> is hydrogen and n is 0 or 1 to 4, and the compound in which R<sup>1</sup> is CH<sub>3</sub> and n is 0 are known. The racemates of compounds of formula (I) in which R<sup>1</sup> is CH<sub>3</sub> and n is 1 or 4 are also known. It is believed that the other compounds of formula (I) including the enantiomers of compounds in which R<sup>1</sup> is CH<sub>3</sub> and n is 1 or 4 are novel. It was not previously known that any of the compounds of formula I have cellular rescue properties.</p>
    <p>Particularly preferred as cellular rescue agents are those compounds of the R configuration.</p>
    <p>The S-enantiomers antagonize the antiapoptotic actions of the R-enantiomers, and are useful as research tools.</p>
    <p>The invention extends to salts of compounds of formula I. For administration the salts should be pharmaceutically acceptable, but other salts may be useful, for example, in synthesis or for purification.</p>
    <p>Compounds of the invention can be prepared in a variety of different ways. One process involves</p>
    <p>(a) reacting a primary amine of formula (II) ##STR4## with a propargyl reactant of formula (III)</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">LCH<sub>2</sub> C.tbd.CH                                         (III)</pre>
    
    <p>wherein L is a leaving group, for example a halide or a (C<sub>1</sub> -C<sub>4</sub>)alkylsulphonyl, tosyl or mesyl group. Bromine is preferred.</p>
    <p>It is possible to use an amine of the formula (II) in which R<sup>1</sup> differs from R<sup>2</sup> in the form of a racemate and to separate enantiomers subsequently, but it is preferred to use an amine in substantially enantiomerically pure form. In one preferred embodiment two equivalents of amine are reacted with one equivalent of the compound of formula III, preferably propargyl bromide to form the required propargylamine and the hydrobromide salt of the amine, which can be isolated and reused, in accordance with the following reaction scheme.</p>
    <p>Two Equivalents Amine and One Equivalent Propargyl Bromide in Ether ##STR5## R<sup>2</sup> =methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl;</p>
    <p>R<sup>1</sup> =hydrogen, methyl;</p>
    <p>Chiral primary amines (R- and S-forms) were prepared by tartrate recrystallization from methanol, except for the butyl analogue. (R)- and (S)-2-Butylamine were purchased from Aldrich Chemical Co.</p>
    <p>Another route to compounds of the invention involves</p>
    <p>(b) reacting a compound of the formula (IV) ##STR6## wherein R<sup>1</sup> and R<sup>2</sup> are as defined above, with alcoholic hydroxide, to remove the trifluoroacetyl group.</p>
    <p>The compound of formula (IV) can be obtained by a process that involves trifluoroacetylation of the amine, followed by propargylation. Again, the amine can be used in racemic or enantiomerically pure form. The amine is reacted with trifluoroacetic anhydride or a trifluoroacetyl halide in an inert organic solvent, for instance a chlorinated hydrocarbon such as methylene dichloride, chloroform or carbon tetrachloride, and a base, for example an organic base such as triethylamine. The N-trifluoroacetylamine is then refluxed with a propargyl compound of formula (III), suitably in the presence of a base such as potassium t-butoxide in a polar organic solvent, for example acetonitrile, and in the presence of a crown ether, for example 18-crown-6. The product of this reaction is then hydrolysed, suitably by reaction with a base such as an alkali metal hydroxide in an alcoholic solution. A preferred embodiment is shown in the following reaction scheme. Trifluoroacetylation of Amine then Propargylation: ##STR7## wherein R<sup>1</sup> and R<sup>2</sup> are as defined above.</p>
    <p>Compounds of formula (I) can also be prepared by (c) reacting a compound of formula (V) ##STR8## wherein R<sup>1</sup> and R<sup>2</sup> are as defined above and R is lower alkyl preferably (C<sub>1</sub> -C<sub>2</sub>) alkyl, with an acid.</p>
    <p>The compound of formula V can be obtained by phosphorylating and then propargylating an amine. Again, the amine can be a racemate but is preferably a substantially pure enantiomer. An amine of formula (II) is reacted with a dialkylphosphite, for example diethyl or dimethyl phosphite, preferably in an organic solvent such as carbon tetrachloride, in the presence of an aqueous hydroxide, such as NaOH, and in the presence of a phase transfer catalyst such as benzyltriethylammonium chloride or tetrabutyl ammonium hydrogen sulfate.</p>
    <p>The phosphorylated amine is then reacted with a propargyl compound of formula (III), preferably in the presence of aqueous base, such as NaOH, in the presence of a phase transfer catalyst, such as tetrabutyl ammonium hydrogen sulfate or benzyltriethylammonium chloride.</p>
    <p>Thereafter it is acidified, to remove the phosphite moiety. A preferred embodiment of this process is set forth below. ##STR9## wherein R<sup>1</sup> and R<sup>2</sup> are as defined above.</p>
    <p>A further aspect of the invention is a pharmaceutical composition comprising a compound of general formula (I) that is achiral or is a substantially enantiomerically pure R-enantiomer, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable excipient, diluent, or adjuvant, for use in treatment of a disease in which cell death occurs by apoptosis.</p>
    <p>Yet a further aspect of the invention is a commercial package containing as active ingredient a compound of formula (I) that is achiral or is a substantially enantiomerically pure R-enantiomer, or a pharmaceutically acceptable salt thereof, together with instructions for its use for the treatment of disease in which cell death occurs by apoptosis.</p>
    <heading>ANTIAPOPTOSIS AND NEUROPROTECTION STUDIES</heading> <p>The following biological data demonstrate that the compounds of the invention exhibit antiapoptotic and neuroprotective properties.</p>
    <p>These data can be interpreted with the aid of the accompanying drawings, of which:</p>
    <p>FIG. 1a is a graph showing the dose-response relationship of inhibition by R-N-(2-heptyl)propargylamine (R-2HPA) of Ara C induced apoptosis.</p>
    <p>FIG. 1b is a graph showing the dose-response relationship of inhibition by (R)-N-(2-heptyl)-N-methylpropargylamine (R-2HMP) of Ara C induced apoptosis.</p>
    <p>FIG. 1c is a graph showing the effect of R-2HMP, S-2HMP, R-deprenyl and S-deprenyl (all 10<sup>-7</sup> M) on Ara C induced apoptosis.</p>
    <p>FIG. 1d is a graph showing that anti-apoptotic compounds do not prevent apoptosis in cerebellar granule cells induced by low concentrations of K<sup>+</sup> in the medium.</p>
    <heading>PHARMACOLOGICAL DATA</heading> <heading>EXAMPLE I</heading> <p>In Vitro Model of Rescue: Cerebellar Granule Cells</p>
    <p>Effect of compounds of the invention for the prevention of apoptosis in cerebellar granule cells.</p>
    <p>Cultures of cerebellar granule cells (CGC) can be induced into apoptosis by the addition of a high concentration of cytosine arabinoside (Ara C) (Dessi et al., 1995) and it has been shown that this is a p53 dependent apoptosis (Enokido et al, 1996). We have measured the antiapoptotic effect of N-(2-heptyl)propargylamine (2HPA) using this system and compared the results to those obtained with previously known aliphatic methyl propargylamines and deprenyl.</p>
    <p>Cultures of CGC were obtained from 6-8 day old Wistar rat pups. Cultures were grown on glass in 35 mm petri dishes for 3 days and then used for experiments. 20 l aliquots of drug solutions (Ara C, anti-apoptotic drugs, drug vehicles) were added to the medium of the cultures. 24 Hours later the cultures were fixed with FAM, and stained with bis-benzamide. Normal and apoptotic nuclei were counted to a total of 90-120 cells per culture. The optimum concentration of Ara C was found to be 100 M. Concentrations in excess of 150 M caused detachment of the cultures.</p>
    <p>R-2HPA had an EC<sub>50</sub> of about 10<sup>-11</sup> M (FIG. 1a). In contrast (R)-N-(2-heptyl)-N-methyl-propargylamine(R-2HMP) had an EC<sub>50</sub> between 10<sup>-9</sup> and 10<sup>-7</sup> M (FIG. 1b). In addition we have demonstrated the stereospecific effect of the R-isomers using aliphatic methyl propargylamines (R-2HMP and S-2HMP) and deprenyls (R-deprenyl and S-deprenyl) (FIG. 1c). R-2HMP and R-deprenyl (10<sup>-7</sup> M) completely blocked the Ara C induced apoptosis while S-2HMP and S-deprenyl (10<sup>-7</sup> M) did not (FIG. 1c). From Table 1 one can confirm that S-2HPA does not have an anti-apoptotic effect. None of these compounds prevented the P53 independent apoptosis that was induced by lowering the concentration of potassium (D'Mello, et al, 1993) in the medium (FIG. 1d).</p>
    <p>It is concluded that Ara C induced apoptosis in cultures of CGC can be blocked by the aliphatic secondary propargylamines of the invention. From the comparison of the effect of the novel compound 2HPA versus that of previously reported 2HMP it is clear that the potency of the aliphatic secondary propargylamines of the invention in the prevention of p53 dependent apoptosis is much greater than the potency of the related known aliphatic methyl propargylamines. The rescue is stereospecific, the S-isomer having no anti-apoptotic effect. Further examination has shown that the S-enantiomers are in fact antagonists of the anti-apoptotic action of the R-enantiomers (lines Ara C+R-2HMP+S-2HMP and Ara C+R-2HMP+S-2HPA of Table 1).</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________(S)-N-(2-heptyl)-N-methyl-propargylamine (S-2HMP)and (S)-N-(2-heptyl)-propargylamine (S-2HPA)antagonistic effect on antiapoptotic action of(R)-N-(2-heptyl)-N-methyl-propargylamine (R-2HMP)Treatment           Percent Apoptotic Nuclei______________________________________Control              4.2  0.3Ara C               14.6  0.9Control + R-2HMP     4.8  0.7Ara C + R-2HMP       6.3  0.8*Control + S-2HMP     5.0  0.6Ara C  S-2HMP   13.7  1.1Ara C + R-2HMP  S-2HMP               15.1  0.9#Control + S-2HPA     4.7  0.7Ara C + S-2HPA      14.2  0.9Ara C + R-2HMP + S-2HPA               13.8  1.2#______________________________________ Values represent the mean  sem of 4 cultures. Compounds were added at the following concentrations: Ara C, 100 M, R2HMP, 100 nM; S2HMP, 10 M; S2HPA, 10 M. *P &lt; 0.05 compared to Ara C alone. #P &lt; 0.05 compared to Ara C + R2HMP.</pre>
    
    <heading>EXAMPLE II</heading> <heading>Hypoxia/ischaemia model</heading> <p>Apoptosis of hippocampal pyramidal neurons can be induced in vivo using a rat model of hypoxia/ischaemia (Paterson et al., 1996). This model produces selective, unilateral lesioning of the pyramidal neurons in the hippocampus which involves neuronal apoptosis.</p>
    <p>This is demonstrated by the results obtained using a compound of the invention N-(2-heptyl)propargylamine (2-HPA). Previously reported (R)-N-(2 heptyl)-N-methyl-propargylamine has an ED<sub>50</sub> between 1 and 10 nmol/kg following subcutaneous administration. These two compounds, and the compounds (R)-N-(2-heptyl)-methylamine and R-(2-heptyl) amine were tested. Most active is R-2HPA (Table 2) and of the other compounds only R-2HMP shows significant activity. The secondary amine (R)-N-(2-heptyl)-methylamine (R-2HMA), and the primary amine (R)-(2-heptyl)amine (R-2HA), neither increase nor decrease the CA1 neuronal death.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________The effect of amine compounds (0.1 mol/kg, s.c.)on CA1 survival in the hypoxia/ischaemia model.Compound          R-isomer  S-isomer______________________________________N-(2-heptyl)-N-methyl-             239  35**                       112  23propargylamine (2HMP)N-(2-heptyl)-propargyl-             320  48**                       131  19amine (2HPA)N-(2-heptyl)-methyl-              85  26                       --amine (2HMA)       90  30                       --(2-heptyl)-amine (2HA)______________________________________ Values are the mean survival of CA1 neurones expressed as a percentage of vehicle treated controls (vehicle = 100%)  sem (n = 6-10). *P &lt; 0.05, **P &lt; 0.01.</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 3______________________________________The effect of oral administration of R-2HMP andR-2HPA on CA1 survival in the hypoxia/ischemia modelTreatment         Percentage survival______________________________________Water             100  22R-2HMP            112  24R-2HPA            230  36*______________________________________ Values are means  sem (n = 7-10) of CA1 survival relative to vehicle controls. Drugs given in a volume of 1 ml per animal, R2HMP and R2HPA at 0.1 mg/kg. *p &lt; 0.01 with respect to water.</pre>
    
    <p>Following oral administration of drugs the aliphatic propargylamine, R-2HPA, is more potent than its aliphatic methyl propargylamine analogue, R-2HMP (Table 3).</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 4__________________________________________________________________________The effects of a variety of aliphatic propargylamines (0.1 mol/kg,s.c.)on CA1 survival in the hypoxia/ischaemia model.__________________________________________________________________________N-methylpropargylamines       Percentage survival                Propargylamines                        Percentage Survival__________________________________________________________________________Branched-chain aliphatic propargylamines and methyl propargylaminesR-2HMP       239  35**                R-2HPA   320  48**S-2HMP      112  23                S-2HPA  131  19R-2BuMP      297  52**                R-2BuPA  263  37**S-2BuMP     139  38                S-2BuMP --2PrMP        255  43**                2PrMP   175  20*Straight chain aliphatic propargylamines and methyl propargylamines1HxMP        215  24*                1HxPA   179  23*1PrMP       127  31                1PrPA   174  29*EMP          82  19                EPA     164  18*DMP         117  28                MPA     78  31__________________________________________________________________________ Values are the mean survival of CA1 neurones expressed as a percentage of vehicle treated controls (vehicle = 100%)  sem (n = 6 - 10). *P &lt; 0.05, **P &lt; 0.01.</pre>
    
    <p>Definition of abbreviations</p>
    <p>R/S-2HMP=(R)/(S)-N-(2-heptyl)-N-methylproparglamine,</p>
    <p>R/S-2BuMP=(R)/(S)-N-(2-butyl)-N-methylpropargylamine,</p>
    <p>2PrMP=N-(2-propyl)-N-methylpropargylamine,</p>
    <p>R/S-2HPA=(R)/(S)-N-(2-heptyl)-propargylamine,</p>
    <p>R/S-2BuPA=(R)/(S)-N-(2-butyl)-propargylamine,</p>
    <p>2PrPA=N-(2-propyl)-propargylamine,</p>
    <p>1HxMP=N-(1-hexyl)-N-methylpropargylamine,</p>
    <p>1PrMP=N-(1-propyl)-N-methylpropargylamine,</p>
    <p>EMP=N-ethyl-N-methylpropargylamine,</p>
    <p>DMP=N,N-dimethylpropargylamine,</p>
    <p>1HxPA=N-hexylpropargylamine,</p>
    <p>1PrPA=N-propylpropargylamine,</p>
    <p>EPA=N-ethylpropargylamine,</p>
    <p>MPA=N-methylpropargylamine.</p>
    <p>A variety of branched chain and straight chain aliphatic secondary propargylamines and their corresponding N-methyl analogues have been tested in the hypoxia/ischaemia model (Table 4). The data confirm that the secondary propargylamines are as efficacious as pre aliphatic N-methyl propargylamines and that in the case of the branched chain compounds the process is stereospecific with the R-enantiomers being active and the S-enantiomers being inactive. The activities of the straight chain compounds, and of the non-chiral 2-propyl amines, N-(2-propyl)-N-methyl-propargylamine (2PrMP) and N-(2-propyl)-propargylamine (2PrPA), show that the chiral centre in the branched chain compounds is not required for activity in these latter compounds, although the activity appears to be slightly lower than those of the optimum branched chain compounds. Interestingly, 1PrMP was inactive but the analogue 1PrPA was active.</p>
    <heading>EXAMPLE III</heading> <heading>Neuroprotective Effect of R-2HPA in Kainate Models</heading> <p>R-2HPA was found to be capable of preventing kainic acid-induced neuronal damage. Heat shock protein-70(HSP70) and delayed c-Fos expressions have been found to be markers for neuronal injury following kainic acid-induced seizures (Zhang et al, 1996). The levels of both proteins were measured 24 h after a single injection of kainate (10 mg/Kg,i.p). The levels (assessed by quantitative immunohistochemical imaging) can be seen in Table 5. R-2-HPA was able to block the expression of both genes in the rat hippocampal CA1 region. This suggests that this compound can rescue these neurons.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 5______________________________________Effect of R-2-HPA on kainate-inducedHSP70 and delayed c-Fos expression in rathippocampal CA1 field.Treatment       HSP70       Delayed c-Fos______________________________________Kainate         10.8  3.1                       18.0  4.5Kainate + R-2HPA            4.6  2.0*                        4.5  3.7*______________________________________ Values are means  sem (n = 5) Kainate (10 mg/Kg, i.p.); Rats with seizures between stages IV severe to severe were used. R2HPA (0.25 mg/Kg, s.c.) was administered 4 h after kainate injection; HSP70 and cFos expression were assessed 24 h after kainate treatment (for details of method please see Zhang et al, 1996). Statistics were performed using ANOVA followed by NewmanKeuls multiple comparisons. *p &lt; 0.01.</pre>
    
    <heading>Inhibition In Vitro of Monoamine Oxidase Activity</heading> <p>The inhibition of the rat liver mitochondrial monoamine A and B activity by R- and S-enantiomers of the compounds of the invention and of the previously reported aliphatic N-methylpropargylamines, (i.e. the corresponding N-methyl analogues) is shown in Table 6. The MAO-B inhibitory activities of the aliphatic propargylamines, i.e. N-(2-butyl)-propargylamine (2BuPA), N-(2-hexyl)-propargylamines (2HxPA) and N-(2-heptyl)-propargylamine (2HPA), are substantially reduced in comparison to those of the N-methyl compounds, N-(2-butyl)-N-methyl-propargylamine (2BuMP), N-(2-hexyl)-N-methyl-propargylamine (2HxMP) and N-(2-heptyl)-N-methyl-propargylamine (2HMP). The R-enantiomers of the aliphatic propargylamines are more active than the S-enantiomers.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 6______________________________________Inhibition of rat liver mitochondrial monoamineoxidase B activities by enantiomers of somealiphatic propargylamines and aliphatic N-methylpropargylamines in vitro      PE           Comparison      (1.9  10<sup>-5</sup> M)                   to most effectiveInhibitors*      IC<sub>50</sub>    MAO-B inhibitor in group______________________________________R-2BuMP    1  10<sup>-6</sup> M                   100%S-2BuMP    2  10<sup>-6</sup> M                   50%R-2BuPA    7  10<sup>-5</sup> M                   1.4%S-2BuPA    5  10<sup>-4</sup> M                   0.2%R-2HxMP    3  10<sup>-8</sup> M                   100%S-2HxMP    7  10<sup>-7</sup> M                   4.3%R-2HxPA    4  10<sup>-6</sup> M                   0.8%S-2HxPA    nm           --R-2HMP     3  10<sup>-8</sup> M                   100%S-2HMP     4  10<sup>-6</sup> M                   0.8%R-2HPA     4  10<sup>-6</sup> M                   0.8%S-2HPA     3  10<sup>-5</sup> M                   0.1%______________________________________</pre>
    
    <p>Results are the average of at least 2 independent triplicate experiments for each compound. -Phenylethylamine was used as the MAO-B substrate. Enzyme activity was assessed using a radiometric method as previously described (Yu et al, 1992).</p>
    <heading>Inhibition In Vivo of Monoamine Oxidase Activity</heading> <p>The acute effect on the brain MAO activities of R-2HPA and R-2HMP following intraperitoneal injection is shown in Table 7. R-2HPA exhibits a weaker inhibitory effect on the mouse brain MAO-B with the ED<sub>50</sub> value 20 fold higher than that of its parent compound R-2HMP, which is 2.5 fold more potent than R-deprenyl. None of the compounds inhibit MAO-A in vivo or in vitro.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 7______________________________________Effect of R-2HMP, R-2HPA and R-deprenyl on mousebrain MAO-B activities after intraperitonealadministration of the drugs                  PE Comparison                  (1.9  10<sup>-5</sup> M) to mostInhibitors* ID<sub>50</sub>  (mg/Kg)                  effective inhibitor______________________________________R-2HMP      0.2        100%R-2HPA      4           5%R-deprenyl  0.5         40%______________________________________</pre>
    
    <p>Results are the average of two independent triplicate experiments for each i.p. dose. The doses were 0.5, 1, 2, 5, 10, 20 mg/Kg. Striata were dissected from the brain two hours after i.p. administration of the drugs. MAO-B activities were then determined immediately (Yu et al 1992). The values were estimated from dose-response curves.</p>
    <heading>Selective gene expression regulation by R-2HPA</heading> <heading>Regulation of superoxide dismutase 1</heading> <p>R-Deprenyl has been proposed to possess neuroprotective effects and one of the proposed mechanisms is that R-deprenyl induces superoxidase dismutase (SOD) activity, which would result in the inactivation of singlet oxygen. The induction of free radicals with the succeeding cascade reactions of lipid peroxidation are known to cause neuronal damage. Regulation of SOD activity is involved in several different pathological situations, such as brain ischemia, aging, and neurodegenerative diseases.</p>
    <p>PC12 cells were used to study the gene regulation of SOD (copper, zinc-dependent type, i.e. SOD1) by (R)-2-heptylpropargylamine (R-2HPA). Previous findings have shown that NGF, R-deprenyl and some aliphatic methylpropargylamines can induce SOD1 mRNA in a dose dependent manner (Li, et al., 1995). The data in Table 8 show that R-2HPA can also stimulate SOD1 gene expression and could therefore have anti-oxidant effects.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 8______________________________________Effect of 2-HPA on SOD1 levels in PC12 cellsTreatment            % of Control______________________________________Control              100  20R-2HPA (1 M)     184  41**______________________________________ Mean  SD (n = 4). **p &lt; 0.01. The SOD1 mRNA levels were detected by Northern Blots using total RNA from cultured PC12 cells treated with R2HPA for 24 hours. The blots were hybridized with SOD1 cDNA probe labelled with P<sup>32</sup>  dCTP and the auto radiographs were scanned by a Beckman spectrometer.</pre>
    
    <heading>R-2HPA down-regulates LNGFR in PC12 cells</heading> <p>LNGFR, also called the p75 NGF receptor, is a 75 kDa transmembrane protein with an incompletely characterized function. p75 has some sequence similarity to the tumor necrosis factor receptors, Fas antigen, CD40 and Apo-1, all of which mediate cell death. p75 expression induces neural cell death constitutively when LNGFR is unbound. Mutant PC12 cells (LNGFR deficiency clone) better survive apoptosis induced by NGF or serum withdrawal than the wild type PC12 cells. Binding by NGF or monoclonal antibody, however, inhibits cell death induced by LNGFR. Thus expression of LNGFR may explain the dependence of some neural cells on NGF for survival (Rabizadeh et al, 1993).</p>
    <p>A recent report using antisense technology also indicated that LNGFR mediates survival or death depending on the stage of sensory neuron development. In this study it was demonstrated that, in vitro, lowering the levels of LNGFR expression in sensory neurons with antisense oligonucleotides largely prevents the NGF-mediated survival of sensory neurons from embryonic day 12 and 15 mice but increases the survival of embryonic day 19 and postnatal day 2 sensory neurons in the absence of NGF. Thus LNGFR is required for NGF-mediated survival in neurons at the stage of target innervation but can mediate an apoptotic signal at a later stage of cell development (Barrett et al., 1994).</p>
    <p>The higher level of LNGFR expression in the central nervous system occurs in the cholinergic neurons of the nucleus basalis of Meynert, the cells most severely affected in Alzheimer's disease, These cells continue to express normal or supranormal amounts of LNGFR mRNA and protein during the neuronal degeneration associated with Alzheimer's disease. In contrast, cholinergic cells of the brainstem that resemble those of the nucleus basalis morphologically do not express LNGFR, nor do they degenerate in Alzheimer's disease.</p>
    <p>Data in Table 9 show that R-2HPA downregulated LNGFR mRNA, suggesting a possible mechanism for the protective effects of R-2HPA.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 9______________________________________Effect on LNGFR mRNA levels in PC12 cellsTreatment            % of Control______________________________________Control              100  5.4R-2HPA (1 M)     68.8  16.4**______________________________________ Mean  SD (n = 4). **p &lt; 0.01. The LNGFR mRNA levels were detected by Northern Blots using total RNA from cultured PC12 cells treated with R2HP for 24 hours. The blots were hybridized with LNGFR cDNA probe labelled with P<sup>32</sup>  dCTP and the auto radiographs were scanned by a Beckman spectrometer.</pre>
    
    <heading>REFERENCES</heading> <p>Barrett G. L. and Bartless P. F. (1994) The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development. Proc. Natl. Aca. U.S.A. 91, 6501-6505.</p>
    <p>D'Mello, S. R., Galli, C., Ciottie T., &amp; Calissano, P. (1993). Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc. Natl. Acad. Sci. U.S.A, 90, 10989-10993.</p>
    <p>Dessi, F., Pollard, H., Moreau, J., Ben-Ari, Y., &amp; Chariaut-Marlangue, C. (1995), Cytosine arabinoside induces apoptosis in cerebellar neurons in culture. J. Neurochem., 64, 1980-1987.</p>
    <p>Enokido, Y., Araki, T., Aizawa, S., &amp; Hatanaka, H.(1996). P53 involves cytosine arabinoside induced apoptosis in cultured cerebellar granule neurons. Neurosci. Lett., 203,1-4.</p>
    <p>Grace, J. M., Kinter, M. T., &amp; MacDonald, T. L. (1994). Atypical metabolism of deprenyl and its enantiomer(s)-(+)-N,-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol., 7,286-290.</p>
    <p>Li, XM., Qi,J., Juorio, A. V. and Boulton, A. A.(1995a) (-)-Deprenyl enhances NGF-induced changes in superoxidase dismutase mRNA in PC12 cells. Proceedings of the 15th Biennial Meeting of International Society for Neurochemistry, Kyoto, Japan, Jul. 2-7, 1995.</p>
    <p>Rabizadeh S., Oh J., Zhong L., Yang J., Bitler C. M., Butcher L. L. and Bredesen D. E. (1993) Induction of apoptosis by the low-affinity NGF receptor. Science, 261,345-348.</p>
    <p>Paterson, I. A. Barber, A. J., Gelowitz, D. L., &amp; Voll, C. (1996). (-)-Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci, Biobehav. Revs., 20, in press.</p>
    <p>Yu, P. H. Davis B. A., &amp; Boulton, A. A. (1992). Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J. Med. Chem., 35,3705-3713.</p>
    <p>Zhang, X., Boulton, A. A., &amp; Yu, P. H. (1996). Expression of heat shock protein-70 and limbic seizure-induced neuronal death in the rat brain. Eur. J. Neurosci, 8, 1432-1440.</p>
    <heading>DETAILED SYNTHETIC PROCEDURES</heading> <p>The following non-limiting examples of synthetic procedures are provided.</p>
    <heading>EXAMPLE 1</heading> <heading>(R)-N-2-Heptylpropargylamine hydrochloride  (R)-N-2-propynyl-2-heptanamine!</heading> <p>(R)-2HPA.HCl ##STR10##</p>
    <p>To a solution of (R)-2-heptylamine(98.6% R) (11.1 g, 96.6 mmol) in anhydrous diethyl ether (165 ml) was added an 80% toluene solution of propargyl bromide (Lancaster Synthesis Inc., Windham, N.H., U.S.A.) (5.38 ml, 48.3 mmol). The solution was stirred under gentle reflux for 3 days. To the cold reaction solution was added 4N HCl (75 ml) and the mixture was evaporated to dryness under reduced pressure at 70 C. The red-orange viscous residue was basified by the addition of 20% NaOH, saturated with NaCl and then extracted with ether (330 ml). The combined extracts were dried over MgSO<sub>4</sub> then concentrated under reduced pressure at 30 C. The product was distilled under reduced pressure (water aspirator: 30 mm). Two fractions were collected: b.p. 55-74 C., 4.3 g=78% (of excess)  (R)-2-heptylamine! and b.p. 98-110 C., 4.3 g=58%  (R)-2-heptylpropargylamine! (based on 48.3 mmol propargyl bromide; 48% if based on 96.6 mmol (R)-2-heptylamine minus 37.4 mmoles recovered). The addition of 25% ethanolic HCl to an ether solution of the free base and cooling in a freezer for several hours resulted in the precipitation of the hydrochloride salt. m.p.=78.5-80 C. The optical purity was assessed by adapting the method of Durden et al (1997) for 2-alkylpropargylamines (% R=99.2).</p>
    <p>Mass spectrum: m/e: 153 (M+); 138 (M-CH<sub>3</sub>); 82 (base peak).</p>
    <p>1H-NMR (D<sub>2</sub> O, 300 MHz): 0.73 (t,3H); 1.17(d,3H); 1.1-1.3(m,6H); 1.43(m,1H); 1.59(m,1H); 2.82(t,1H); 3.32(m,1H); 3.79(t,2H).</p>
    <p>Elemental Analysis: Calc: % C=63.30; % H=10.63; % N=7.38.</p>
    <p>Found: % C=63.56; % H=10.49; % N=7.15.</p>
    <p>The starting material, (R)-2-heptylamine, was prepared as follows:</p>
    <p>Racemic 2-heptylamine was resolved by repeated recrystallizations of its L-tartrate salt from methanol according to the method of Mazur (1970). Seven recrystallizations using a ratio of volume of methanol to weight of tartrate salt of 2.4 to 2.6 (increasing as the optical purity increased) gave the R-enantiomer with a purity of 98.6% R. In a separate experiment, after nine recrystallizations, the optical purity was 99.7% R. The optical purity was determined by derivatization with the chiral reagent(S)-N-trifluoroacetylprolyl chloride and then gas chromatography on a chiral column to resolve the diastereomers. (Durden et al., 1997).</p>
    <heading>EXAMPLE 2</heading> <heading>(R)-N-2-Heptylpropargylamine hydrochloride (R)-N-2-propynyl-2-heptanamine!</heading> <p>(R)-2HPA.HCl ##STR11##</p>
    <p>Crude (R)-N-trifluoroacetyl-N-2-heptylpropargylamine (7.3 g) was dissolved in 2N methanolic KOH (70 ml) and stirred at room temperature for 2 days. The reaction mixture was cooled in an ice-water bath and acidified with 20% methanolic HCl (75 ml). The precipitated KCl was filtered, washed with a little methanol and the combined filtrates were evaporated to dryness. The residue was basified with 10% NaOH (50 ml), saturated with NaCl and extracted with ether (225 ml). After drying over MgSO<sub>4</sub>, most of the solvent was removed by rotary evaporation at 30 C. The residue (3.0 g) was distilled at 30 mm (water aspirator) to give a clear colourless liquid (boiling range 132-150 C.), 1.90 g. The hydrochloride salt was prepared as described in Example 1, Method 1.</p>
    <p>Melting point, mass spectrum and 1H-NMR: as above (Example 1, Method 1).</p>
    <p>The starting material, (R)-2-Heptylamine, was prepared according to Example 1.</p>
    <heading>(R)-N-Trifluoroacetyl-2-heptylamine ##STR12##</heading> <p>To a stirred ice-cold solution of (R)-2-heptylamine (3.5 g, 30 mmol) in chloroform (35 ml) and pyridine (6 ml) was added dropwise trifluoroacetic anhydride (6 ml, 38 mmol). After completion of the addition the solution was stirred overnight at room temperature. The solution was washed successively with 10% citric acid (315 ml) and saturated aqueous sodium bicarbonate solution (220 ml). The organic solution was dried over Na<sub>2</sub> SO<sub>4</sub>, filtered and the solvent was removed under reduced pressure at 40 C. The residue was a yellow liquid obtained in quantitative yield.</p>
    <p>Mass spectrum: m/e: 211(M+); 196(M-CH<sub>3</sub>); 140(base peak).</p>
    <heading>(R)-N-Trifluoroacetyl-N-2-heptylpropargylamine ##STR13##</heading> <p>To a solution of N-trifluoroacetyl-N-2-heptylamine(6.33 g, 30 mmol) in CH<sub>3</sub> CN (75 ml)/t-butanol(0.5 ml) was added 18-crown-6(300 mg) and powdered potassium t-butoxide (3.36 g, 30 mmol). After stirring for 15 min most of the solids had dissolved and propargyl bromide (80% in toluene) (3.5 ml, 31.5 mmol) was then added dropwise. The solution was stirred at 80-85 C. (oil bath temperature) for 24 h during which time the solution became brown in color and a white solid precipitated. After the reaction mixture had cooled to room temperature, dichloromethane (75 ml) was added and the solids were filtered with suction and washed with dichloromethane. The weight of the solids (KBr) was 3.6 g (theoretical:3.57 g). The combined filtrates were rotary evaporated to give 7.3 g of a dark brown liquid (theoretical yield=7.47 g). The product was not purified but used directly in the next step.</p>
    <p>Mass Spectrum: m/e:249(M+); 234(M-CH<sub>3</sub>); 178 (base peak); 140;39.</p>
    <heading>EXAMPLE 3</heading> <heading>N-2-Propylpropargylamine hydrochloride  N-2-propynyl-2-propanamine!</heading> <p>2PrPA</p>
    <p>The hydrochloride salt precipitated immediately on addition of HCl: m.p.=188.5-189 C.</p>
    <p>Mass Spectrum:m/e:97(M+); 82(M-CH<sub>3</sub>) (base peak).</p>
    <p>1H-NMR (D<sub>2</sub> O, 300 MHz): 3.77(d,2H); 3.41(m,1H); 2.81(t,1H); 1.19(d,6H).</p>
    <heading>EXAMPLE 4</heading> <heading>(R)-N-2-Butylpropargylamine hydrochloride (R)-N-2-propynyl-2-butanamine!</heading> <p>(R)-2BuPA</p>
    <p>The starting (R)-2-butylamine(93.1% R) was purchased from Aldrich Chemical Co., Milwaukee, Wis., U.S.A. The hydrochloride salt of 2BuPA precipitated immediately on addition of HCl: m.p.=136-137 C. Optical purity=98.4% R</p>
    <p>Mass Spectrum: m/e: 111(M+); 96(M-CH<sub>3</sub>); 82(base peak).</p>
    <p>1H-NMR(D<sub>2</sub> O, 300 MHz): 3.79(d,2H); 3.24(m,1H); 2.81(t,1H); 1.65(m,1H); 1.45(m,1H); 1.17 (d,3H); 0.82 (t,3H).</p>
    <heading>EXAMPLE 5</heading> <heading>(R)-N-2-Pentylpropargylamine hydrochloride  (R)-N-2-propynyl-2-pentanamine!</heading> <p>(R)-2PePA</p>
    <p>The hydrochloride salt precipitated immediately on addition of HCl: m.p=107-108 C. Optical purity=99.5% R</p>
    <p>Mass Spectrum: m/e:125(M+); 110(M-CH<sub>3</sub>); 82(base peak).</p>
    <p>1H-NMR(D<sub>2</sub> O, 300 MHz): 3.78 (d,2H); 3.32(m,1H); 2.80(t,1H); 1.56(m,1H); 1.40(m,1H); 1.23(m,2H); 1.15 (d,3H); 0.78(t,3H).</p>
    <p>Elemental Analysis: Calc: % C=59.43; % H=9.98; % N=8.66 Found: % C=59.97; % H=9.26; % N=8.37.</p>
    <heading>EXAMPLE 6</heading> <heading>(R)-N-2-Hexylpropargylamine hydrochloride (R)-N-2-propynyl-2-hexanamine!</heading> <p>(R)-2HxPA</p>
    <p>The hydrochloride salt precipitated on addition of HCl only after cooling in the freezer for several hours: m.p=96-97 C. Optical purity=97.1% R</p>
    <p>Mass Spectrum: m/e: 139(M+); 125(M-CH<sub>3</sub>); 82(base peak).</p>
    <heading>EXAMPLE 7</heading> <heading>(R)-N-2-Octylpropargylamine hydrochloride (R)-N-2-propynyl-2-octanamine!</heading> <p>(R)-20PA</p>
    <p>The hydrochloride salt precipitated on addition of HCl only after cooling in the freezer for several hours: m.p.=78.5-79.5 C. Optical purity=99.4% R.</p>
    <p>Mass Spectrum: m/e: 167 (M+); 152 (M-CH<sub>3</sub>); 82 (base peak).</p>
    <p>1H-NMR(D<sub>2</sub> O, 300 MHz): 3.80(d,2H); 3.30(m,1H); 2.81(t,1H); 1.60(m,1H); 1.43(m,1H); 1.23(m,2H); 1.15(d+m,11H); 0.71 (t,3H).</p>
    <heading>EXAMPLE 8</heading> <heading>N-1-Propylpropargylamine hydrochloride N-2-propynyl-1-propanamine!</heading> <p>1PrPA</p>
    <p>The hydrochloride salt precipitated immediately on addition of HCl: m.p.=146-147 C.</p>
    <p>Mass Spectrum: m/e: 97(M+); 68(base peak).</p>
    <p>1H-NMR(D<sub>2</sub> O, 300 MHz): 3.79(d,2H); 2.98(t,3H): 2.85(t,1H); 1.57(m,2H); 0.85(t,3H).</p>
    <heading>EXAMPLE 9</heading> <heading>N-1-Butylpropargylamine hydrochloride N-2-propynyl-1-butanamine!</heading> <p>1BuPA</p>
    <p>The hydrochloride salt precipitated immediately on addition of HCl: m.p.=167-168 C.</p>
    <p>Mass Spectrum: m/e:111(M+); 96(M-CH<sub>3</sub>); 68(base peak).</p>
    <p>1H-NMR (D<sub>2</sub> O, 300 MHz): 3.75(d,2H); 3.00(t,3H); 2.81(t,1H); 1.50(m,2H); 1.23(m,2H); 0.78 (t,3H).</p>
    <heading>EXAMPLE 10</heading> <heading>N-1-Pentylpropargylamine hydrochloride  N-2-propynyl-1-pentanamine!</heading> <p>1PePA</p>
    <p>The hydrochloride salt precipitated immediately on addition of HCl: m.p.=170-171 C.</p>
    <p>Mass Spectrum: m/e: 125(M+); 110(M-CH<sub>3</sub>); 68(base peak).</p>
    <p>1H-NMR(D<sub>2</sub> O, 300 MHz): 3.79(d,2H); 3.02(t,3H); 2.83(t,1H); 1.57(m,2H); 1.22(m,4H); 0.78(t,3H).</p>
    <heading>EXAMPLE 11</heading> <heading>N-1-Hexylpropargylamine hydrochloride  N-2-propynyl-1-hexanamine!</heading> <p>1HxPA</p>
    <p>The hydrochloride salt precipitated immediately on addition of HCl: m.p.=170-171 C.</p>
    <p>Mass Spectrum: m/e: 139(M+); 125(M-CH<sub>3</sub>); 68(base peak).</p>
    <heading>REFERENCES</heading> <p>Durden, D. A.; Davis, B. A.; Boulton, A. A., (1997) "Enantioselective gas chromatographic assay of 2-alkylamines using N-(trifluoroacetyl) prolyl derivatives and a chiral capillary column." J. Chromatography B 689:165-173.</p>
    <p>Mazur, R. H. (1970). "Absolute configuration of 1-methylalkylamines." J. Organic Chemistry 35: 2050-2051</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5169868">US5169868</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 1, 1991</td><td class="patent-data-table-td patent-date-value">Dec 8, 1992</td><td class="patent-data-table-td ">University Of Saskatchewan</td><td class="patent-data-table-td ">Antidepressants, enzyme inhibitors; alleviating parkinsonism, alzheimer&#39;s disease</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ansari et al., J. Neuroscience, 13(9), 4042 4053 (1993).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ansari et al., J. Neuroscience, 13(9), 4042-4053 (1993).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Berry et al., Progress in Neurobiology, 44, 141 161 (1994).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Berry et al., Progress in Neurobiology, 44, 141-161 (1994).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Boissier et al., Therapie, XXII, 367 373 (1967) (See English Summary on p. 373).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Boissier et al., Therapie, XXII, 367-373 (1967) (See English Summary on p. 373).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Davis et al., American Society for Neurochemistry (Mar. 1995) (Abstract).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Finberg et al., J. Neural Transm., 48, 95 101 (1996).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Finberg et al., J. Neural Transm., 48, 95-101 (1996).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Grace et al., Chem. Res. Toxicol., 7, 286 290 (1994).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Grace et al., Chem. Res. Toxicol., 7, 286-290 (1994).</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Knollema et al., Stroke, 26(10), 1883 1887 (1995).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Knollema et al., Stroke, 26(10), 1883-1887 (1995).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Lai et al., Toxicology and Applied Pharmacology, 142, 186 191 (1997).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lai et al., Toxicology and Applied Pharmacology, 142, 186-191 (1997).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Mytilineou et al., J. Neurochemistry, 68(1), 33 39 (1997).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mytilineou et al., J. Neurochemistry, 68(1), 33-39 (1997).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Mytilineou et al., J. Neurochemistry, 68(1), 434 436 (1997).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mytilineou et al., J. Neurochemistry, 68(1), 434-436 (1997).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Oh et al., J. Neuroscience Research, 38, 64 74 (1994).</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Oh et al., J. Neuroscience Research, 38, 64-74 (1994).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Paterson et al., J. Neurochemistry, (in press) (1997).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Paterson et al., Neuroscience and Biobehavioral Reviews, 20, 1 6 (1996).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Paterson et al., Neuroscience and Biobehavioral Reviews, 20, 1-6 (1996).</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Paterson et al., Society for Neuroscience, 23, Abstract 880.6 (1997).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Rideout et al., Society for Neuroscience, 23, Abstract 34.4 (1997).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Salo et al., J. Neuroscience Research, 31, 394 400 (1992).</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Salo et al., J. Neuroscience Research, 31, 394-400 (1992).</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Tatton et al., J. Neurochemistry, 63(4), 1572 1575 (1994).</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tatton et al., J. Neurochemistry, 63(4), 1572-1575 (1994).</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Tatton et al., J. Neuroscience Research, 30(4), 666 672 (1991).</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tatton et al., J. Neuroscience Research, 30(4), 666-672 (1991).</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Tatton et al., Neurology, 47(3), S171 S183 (1996).</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tatton et al., Neurology, 47(3), S171-S183 (1996).</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Wu et al., J. Neural Trasm., 100, 53 61 (1995).</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wu et al., J. Neural Trasm., 100, 53-61 (1995).</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Yoles et al., Society for Neuroscience, 21, 562, Abstract 230.18 (1995).</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Yoshida et al., Xenobiotica, 16(2), 129 136 (1986).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yoshida et al., Xenobiotica, 16(2), 129-136 (1986).</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Yu et al., J. Medicinal Chemistry, 35(20), 3705 3713 (1992).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yu et al., J. Medicinal Chemistry, 35(20), 3705-3713 (1992).</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Yu et al., J. Neurochemistry, 63(5), 1820 1828 (1994).</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yu et al., J. Neurochemistry, 63(5), 1820-1828 (1994).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Yu et al., N. Neurochemistry, 62(2), 697 704 (1994).</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yu et al., N. Neurochemistry, 62(2), 697-704 (1994).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6809120">US6809120</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 13, 1999</td><td class="patent-data-table-td patent-date-value">Oct 26, 2004</td><td class="patent-data-table-td ">University Of Saskatchewan Technologies Inc.</td><td class="patent-data-table-td ">Protecting normal cells; overcoming drug resistance and/or toxicity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8058442">US8058442</a></td><td class="patent-data-table-td patent-date-value">Nov 7, 2003</td><td class="patent-data-table-td patent-date-value">Nov 15, 2011</td><td class="patent-data-table-td ">Technion Research And Development Foundation Ltd.</td><td class="patent-data-table-td ">Neuroprotective iron chelators and pharmaceutical compositions comprising them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8097608">US8097608</a></td><td class="patent-data-table-td patent-date-value">Jun 9, 2006</td><td class="patent-data-table-td patent-date-value">Jan 17, 2012</td><td class="patent-data-table-td ">Technion Research And Development Foundation Ltd.</td><td class="patent-data-table-td ">Use of propargylamine or derivative including including N-propargyl-1-aminoindane as protective agent; preventing apoptosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8263655">US8263655</a></td><td class="patent-data-table-td patent-date-value">Oct 6, 2005</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Technion Research And Development Foundation Ltd</td><td class="patent-data-table-td ">Methods for treatment of renal failure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20060287401">US20060287401</a></td><td class="patent-data-table-td patent-date-value">Jun 9, 2006</td><td class="patent-data-table-td patent-date-value">Dec 21, 2006</td><td class="patent-data-table-td ">Technion Research And Development Foundation Ltd.</td><td class="patent-data-table-td ">Methods for treatment of cardiovascular disorders and diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2433626A1?cl=en">EP2433626A1</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2004</td><td class="patent-data-table-td patent-date-value">Mar 28, 2012</td><td class="patent-data-table-td ">Technion Research &amp; Development Foundation Ltd.</td><td class="patent-data-table-td ">Compositions and Methods for Treatment of Cardiovascular Disorders and Diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2000074726A1?cl=en">WO2000074726A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 7, 2000</td><td class="patent-data-table-td patent-date-value">Dec 14, 2000</td><td class="patent-data-table-td ">David Gladstone Inst</td><td class="patent-data-table-td ">METHODS AND COMPOSITIONS FOR PREVENTING p53 MEDIATED APOPTOSIS</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007039909A2?cl=en">WO2007039909A2</a></td><td class="patent-data-table-td patent-date-value">Oct 5, 2006</td><td class="patent-data-table-td patent-date-value">Apr 12, 2007</td><td class="patent-data-table-td ">Technion Res &amp; Dev Foundation</td><td class="patent-data-table-td ">Compositions and methods for treatment of renal failure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011095973A1?cl=en">WO2011095973A1</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2011</td><td class="patent-data-table-td patent-date-value">Aug 11, 2011</td><td class="patent-data-table-td ">Pharma Two B Ltd.</td><td class="patent-data-table-td ">Extended release formulations of rasagiline and uses thereof</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc564/defs564.htm&usg=AFQjCNF9-HmMeafC0bQPhnrFQknDzKD8KQ#C564S409000">564/409</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0025280000">A61P25/28</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031130000">A61K31/13</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07C0211230000">C07C211/23</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0025160000">A61P25/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0025140000">A61P25/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0027020000">A61P27/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0043000000">A61P43/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0009000000">A61P9/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0025000000">A61P25/00</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=r-VIBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07C211/23">C07C211/23</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07C211/23</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Jan 11, 2011</td><td class="patent-data-table-td ">FP</td><td class="patent-data-table-td ">Expired due to failure to pay maintenance fee</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20101124</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 24, 2010</td><td class="patent-data-table-td ">LAPS</td><td class="patent-data-table-td ">Lapse for failure to pay maintenance fees</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 28, 2010</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">May 11, 2006</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 25, 2005</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 1 AND 6 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 2-5 AND 7-9, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 3, 2003</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20030220</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 15, 2002</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 14, 1997</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SASKATCHEWAN, UNIVERSITY OF, CANADA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DURDEN, DAVID;DAVIS, BRUCE;DYCK, LILLIAN;AND OTHERS;REEL/FRAME:008688/0442;SIGNING DATES FROM 19970625 TO 19970626</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2W_XNFzSGZps-0P9nu7xef-Iu8Hw\u0026id=r-VIBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0-PeuSSmyoItF_VF8vM_HvQbDNHw\u0026id=r-VIBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U1bLqtEgNC4_1AgdCxlNf-xgYapFg","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Useful_in_the_treatment_and_prevention_o.pdf?id=r-VIBAABERAJ\u0026output=pdf\u0026sig=ACfU3U2_0bTcI7-WO3MXjfITTc6IjP6KYw"},"sample_url":"http://www.google.com/patents/reader?id=r-VIBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>